Drug Search Results
More Filters [+]

Orbcel-C

Alternative Names: Orbcel-C
Latest Update: 2024-07-11
Latest Update Note: Clinical Trial Update

Product Description

selected Mesenchymal stromal cells derived from human umbilical cord

Mechanisms of Action: Cell Therapy

Novel Mechanism: No

Modality: Cell Therapy

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Belfast Health and Social Care Trust
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Orbcel-C

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Kidney Diseases|ANCA Vasculitis

Phase 2: Acute Respiratory Distress Syndrome|Cholangitis, Sclerosing|Hepatitis, Autoimmune

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

Merlin

P2

Active, not recruiting

Cholangitis, Sclerosing|Hepatitis, Autoimmune

2023-11-23

Repair of ARDS by Stromal Cell Administration (REALIST)

P2

Unknown status

Acute Respiratory Distress Syndrome

2021-12-06

TXCoronavac

P3

Not yet recruiting

Kidney Diseases|ANCA Vasculitis

2021-02-01

Recent News Events